LUCIANA DE PAULA SAMORANO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
12 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 12
bookPart Fotoproteção(2022) MIOTTO, Isadora Zago; SAMORANO, Luciana de Paula; OLIVEIRA, Zilda Najjar Prado de- Tuberous sclerosis complex: review based on new diagnostic criteria(2018) PORTOCARRERO, Larissa Karine Leite; QUENTAL, Klicia Novais; SAMORANO, Luciana Paula; OLIVEIRA, Zilda Najjar Prado de; RIVITTI-MACHADO, Maria Cecilia da MattaTuberous sclerosis complex is a multisystemic, autosomal dominant genetic disorder with complete penetrance, that can evolve with hamartomas in multiple organs, such as skin, central nervous system, kidney and lung. Due to the wide phenotypic variability, the disease is often not recognized. Tuberous sclerosis complex affects one in 10,000 newborns and most patients are diagnosed during the first 15 months of life. The diagnostic criteria for tuberous sclerosis were reviewed in 2012, at the second International Tuberous Sclerosis Complex Consensus Conference. The diagnosis is based on genetic criteria, by the identification of inactivating pathogenic mutation of tumor suppressor genes TSC1 and TSC2, and clinical criteria, including cutaneous, renal, pulmonary, cardiac and neurological manifestations. The treatment of tuberous sclerosis complex consists, mainly, in management of the symptoms caused by hamartomas and in prevention of organ failure. Multidisciplinary approach is recommended, in order to obtain better clinical outcomes.
conferenceObject Darier disease: Long-term treatment with systemic retinoids at a tertiary hospital(2020) VIEIRA, Marina Lino; OLIVEIRA, Zilda Najjar Prado de; SAMORANO, Luciana Paula; PESS, Daiana; RIVITTI-MACHADO, Maria Cecilia- Underrecognition of epidermolysis bullosa pruriginosa(2015) CHA, Caroline Coronado; SAMORANO, Luciana Paula; DACACHE, Fernanda Motta; RIVITTI-MACHADO, Maria Cecilia da Matta; OLIVEIRA, Zilda Najjar Prado de
- Darier disease: long-term treatment with systemic retinoids at a tertiary hospital(2020) VIEIRA, Marina Lino; SAMORANO, Luciana de Paula; RIVITTI-MACHADO, Maria Cecilia da Matta; OLIVEIRA, Zilda Najjar Prado de
- Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol(2017) ROTTER, Anita; SAMORANO, Luciana Paula; LABINAS, Glaucia Helena de Oliveira; ALVARENGA, Juliana Gobbi; RIVITTI-MACHADO, Maria Cecilia; BOUER, Marcio; SANTOS, Paulo C. C.; SILVESTRE, Daniel A. M.; OLIVEIRA, Zilda Najjar Prado deBackgroundInfantile hemangiomas (IHs) are the most common benign vascular tumors of childhood. Propranolol is an effective drug in treating IH. A reliable and complementary instrument is necessary to evaluate IH response to propranolol in addition to clinical and photographic assessments. Ultrasonography is a simple and non-invasive technique that enables precise measurements of tumor size and contributes to objective follow-up. ObjectiveTo demonstrate the use of serial ultrasonography as an adjunctive tool for assessment of IH treatment with propranolol. Patients and methodsA retrospective study of 19 patients with IH treated with propranolol was conducted from January 2009 to March 2014. Data of individual IH volume at the beginning and at least 6 months after the onset of treatment and overall volume reduction by ultrasonographic measurement were obtained. ResultsWe observed a statistically significant IH volume reduction of approximately 0.51 cm(3). This volume corresponds to an average reduction of 47% in the final volume compared with the initial volume. ConclusionUltrasonographic measurements contribute to demonstrate tumor regression and IH response to propranolol. Thus, ultrasonography is an important instrument to guide therapeutic strategies.
bookPart Principais dermatoses na infância(2022) SAMORANO, Luciana de Paula; OLIVEIRA, Zilda Najjar Prado de- Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center(2019) AMARAL, Alexandre Franco; OLIVEIRA, Martina Rodrigues de; DIAS, Olivia Meira; ARIMURA, Fabio Eiji; FREITAS, Carolina Salim Goncalves; ACENCIO, Milena Marques Pagliarelli; ALVARENGA, Vanessa Adelia de; KAIRALLA, Ronaldo Adib; CARVALHO, Carlos Roberto Ribeiro; BALDI, Bruno Guedes; SCLEROSIS, Tuberous; BALBO, Bruno Eduardo Pedroso; WATANABE, Elieser Hitoshi; SAMORANO, Luciana Paula; ONUCHIC, Luiz Fernando; RIVITTI-MACHADO, Maria Cecilia da Matta; MANREZA, Maria Luiza Giraldes de; CORDEIRO, Mauricio Dener; TAKAHASHI, Patricia; OLIVEIRA, Zilda Najjar Prado deIntroductionSerum vascular endothelial growth factor-D (VEGF-D) is a lymphangiogenic growth factor that is considered a valuable tool in the diagnosis of lymphangioleiomyomatosis (LAM). Previous studies have reported a wide variability in VEGF-D serum levels in LAM patients and it seems to be associated with pulmonary impairment and lymphatic involvement.MethodsWe conducted a cross-sectional study from 2009 to 2017 that evaluated VEGF-D serum levels in a cohort of LAM patients who were never treated with mTOR inhibitors and compared them to healthy age-matched volunteers. Clinical and functional parameters were assessed and correlated with their respective serum VEGF-D levels.ResultsOne hundred and four patients were included in the analysis. Serum VEGF-D levels were higher in LAM patients compared to healthy controls: 796 (404-1588) versus 162 (117-232)pg/mL, respectively (p<0.001). Patients with tuberous sclerosis complex-LAM, TSC-LAM (20%), had higher levels of VEGF-D when compared to patients with sporadic LAM (80%) [1005 (641-2732) vs. 772 (370-1383), p=0.05]. Serum VEGF-D levels were weakly correlated with DLCO (r=-0.26, p=0.001) and lymphatic involvement was more frequent in those with serum VEGF-D levels equal or above 800pg/mL (35% vs. 13%, p=0.02).ConclusionsIn LAM, serum VEGF-D is weakly associated with lung function impairment and strongly associated with lymphatic involvement. VEGF-D is validated for use in Brazilian patients with LAM whose characteristics must be accounted for when evaluating their serum VEGF-D levels.
bookPart Dermatoses do recém-nascido(2022) BESSA, Vanessa Rolim; SAMORANO, Luciana de Paula; OLIVEIRA, Zilda Najjar Prado debookPart Afecções fisiológicas da pele do recém-nascido(2022) BESSA, Vanessa Rolim; SAMORANO, Luciana de Paula; OLIVEIRA, Zilda Najjar Prado de